



SHL/SEC/2025

November 04, 2025

**The Bombay Stock Exchange Limited
Listing Department,
1st Floor, New Trading Ring,
Rotunda Building,
Phiroze JeeJeeBhoy Towers, Dalal Street,
Fort
Mumbai – 400 001.
Company Code: 537253**

**The Calcutta Stock Exchange Ltd.
7, Lyons Range
Kolkata - 700 001 India**

Dear Sir,

Sub. : Outcome of the 265th Board Meeting held on 04.11.2025

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we are pleased to inform, that the Board of Directors of the Company at their Board Meeting held on Tuesday, November 04, 2025 interalia approved Un-Audited Financial Results (standalone and consolidated) for the 2nd quarter/ 1st half year ended September 30, 2025 of the FY 2025-26.

Copy of the approved Un-Audited Financial Results (standalone and consolidated) for the 2nd quarter/ 1st half year ended September 30, 2025 of the FY 2025-26 alongwith the Limited Review report thereon are enclosed herewith.

The Board meeting was started at 4:20 p.m. **concluded at 6:25 p.m.**

You are requested to take the above information in your record and oblige us.

Thanking you,

Yours sincerely,
for **Sunil Healthcare Limited**

**Satyendu Pattnaik
Company Secretary & Compliance Officer
FCS-7736
Encl. a/a**

Sunil Healthcare Ltd.

38E/252-A, Vijay Tower, Opp Panchsheel Park Comm. Complex, New Delhi -110049

T: +91 -11-49435555/00, F: +91 -11-43850087 Email : info@sunilhealthcare.com, Web: www.sunilhealthcare.com

CIN No. : L24302DL1973PLC189662

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2025

Particulars	Standalone					Year Ended	Consolidated					Rs. in Lakhs
	Quarter ended		Half Year Ended			Standalone	Quarter ended		Half Year Ended			Year Ended Consolidated
	30th September 2025	30th June 2025	30th September 2024	30th September 2025	30th September 2024		30th September 2025	30th June 2025	30th September 2024	30th September 2025	30th September 2024	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from Operations	2,351.76	2,264.20	2,025.77	4,615.96	4,175.32	8,342.11	2,351.76	2,264.20	2,025.77	4,615.96	4,175.32	8,342.11
2 Other Income	21.02	23.42	19.33	44.44	29.72	135.17	42.06	85.81	17.65	127.87	31.79	133.91
3 Total Income (1+2)	2,372.78	2,287.62	2,045.10	4,660.40	4,205.04	8,477.28	2,393.82	2,350.01	2,043.42	4,743.83	4,207.11	8,476.02
4 Expenses												
a) Cost of Materials consumed	863.60	942.78	946.69	1,806.38	1,867.93	3,849.78	863.60	942.78	946.69	1,806.38	1,867.93	3,849.78
b) Purchase of Stock-in-trade	0.11	2.55	4.65	2.66	10.70	15.80	0.11	2.55	4.65	2.66	10.70	15.80
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(53.19)	1.60	(64.14)	(51.59)	26.94	(199.46)	(53.19)	1.60	(62.52)	(51.59)	27.75	(198.65)
d) Employees benefit expenses	332.15	320.19	285.23	652.34	575.77	1,179.58	332.15	320.19	285.23	652.34	575.77	1,179.58
e) Finance Costs	139.58	144.36	149.97	283.94	301.43	646.11	139.58	144.36	149.97	283.94	301.43	646.11
f) Depreciation and amortisation expense	164.26	166.16	150.60	330.42	299.03	635.43	164.26	166.16	150.62	330.42	299.10	635.49
g) Other Expenses	816.69	668.97	565.35	1,485.66	1,110.85	2,309.44	816.94	669.20	620.10	1,486.14	1,240.43	2,469.48
Total Expenses	2,263.20	2,246.61	2,038.35	4,509.81	4,192.65	8,436.68	2,263.45	2,246.84	2,094.74	4,510.29	4,323.11	8,597.59
5 Profit before tax (3-4)	109.58	41.01	6.75	150.59	12.39	40.60	130.37	103.17	(51.32)	233.54	(116.00)	(121.57)
6 Tax Expenses (Net)	30.68	12.39	3.51	43.07	7.96	20.09	30.68	12.39	3.51	43.07	7.96	20.09
a) Current Tax	-	-	-	-	-	-	-	-	-	-	-	-
i) For Current year	26.73	12.13	5.76	38.86	5.76	8.94	26.73	12.13	5.76	38.86	5.76	8.94
ii) For Earlier year	-	-	-	-	-	-	-	-	-	-	-	-
b) Deferred Tax Charged/(Credit)	-	-	-	-	-	-	-	-	-	-	-	-
i) For Current year	3.95	0.26	(2.25)	4.21	2.20	(3.80)	3.95	0.26	(2.25)	4.21	2.20	(3.80)
ii) For Earlier year	-	-	-	-	-	-	-	-	-	-	-	-
7 Profit/(loss) after tax	78.90	28.62	3.24	107.52	4.43	20.51	99.69	90.78	(54.83)	190.47	(123.96)	14.95
8 Other Comprehensive Income (OCI)	(12.72)	(12.72)	(12.72)	(25.44)	(25.44)	(59.35)	(46.35)	(54.39)	22.45	(100.74)	52.52	(141.66)
a) Items that will not be reclassified to Profit or Loss (net of tax)	(12.72)	(12.72)	(12.72)	(25.44)	(25.44)	(59.35)	(12.72)	(12.72)	(12.72)	(25.44)	(25.44)	(59.35)
b) Items that will be reclassified to Profit or Loss (net of tax)	-	-	-	-	-	-	(33.63)	(41.67)	35.17	(75.30)	77.96	85.95
9 Total Comprehensive Income	66.18	15.90	(9.48)	82.08	(21.01)	(38.84)	53.34	36.39	(32.38)	89.73	(71.44)	(115.06)
10 Paid-up equity share capital (Face value per share Rs.10/-)	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48
11 Other Equity (excluding revaluation reserve)	-	-	-	-	-	4,667.40	-	-	-	-	-	-
12 Earning per share of Rs.10/- each(not annualised)												
(a) Basic (Rs.)	0.77	0.28	0.03	1.05	0.04	0.20	0.97	0.89	(0.53)	1.86	(1.21)	(1.38)
(b) Diluted (Rs.)	0.77	0.28	0.03	1.05	0.04	0.20	0.97	0.89	(0.53)	1.86	(1.21)	(1.38)



Statement of Assets and Liabilities

Particulars	Standalone		Consolidated	
	As at 30th	As at	As at 30th	As at
	September 2025	31st March 2025	September 2025	31st March 2025
	Un-audited	Audited	Un-audited	Audited
A ASSETS				
1 Non Current Assets				
(a) Fixed Assets				
(i) Property, Plant and Equipment	6,070.36	6,192.88	6,070.36	6,192.88
(ii) Capital Work-in-Progress	18.12	9.32	18.12	9.32
(iii) Right of Use Assets	3,177.98	3,211.14	3,177.98	3,211.14
(iv) Other Intangible Assets	3.09	4.24	3.09	4.24
(b) Financial Assets				
(i) Investment	0.10	0.10	-	-
(ii) Other financial assets	173.86	149.17	175.38	150.48
(c) Other non-current Assets	105.12	115.27	105.12	115.27
2 Current Assets				
(a) Inventories	1,714.03	1,673.77	1,840.97	1,764.45
(b) Financial Assets				
(i) Investments	10.00		10.00	
(ii) Trade Receivables	4,598.69	4,850.18	3,886.99	4,164.22
(iii) Cash and Cash Equivalents	10.42	2.37	11.22	3.07
(iv) Other Bank Balances	247.77	305.47	247.77	305.47
(v) Loan	53.28	51.35	-	-
(vi) Other Financial Assets	67.71	86.65	30.49	47.64
(c) Current Tax Assets	-	-	-	-
(d) Other Current Assets	275.20	169.21	340.92	226.00
TOTAL ASSETS	16,525.73	16,821.12	15,918.41	16,194.18
B EQUITY AND LIABILITIES				
1 Equity				
(a) Equity Share Capital	1,025.48	1,025.48	1,025.48	1,025.48
(b) Other Equity	6,422.15	6,340.06	5,770.87	5,681.14
2 Non Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	1,552.12	1,940.13	1,552.12	1,940.13
(b) Provisions	166.75	152.33	166.75	152.33
(c) Deferred Tax Liabilities (Net)	1,131.41	1,134.92	1,131.41	1,134.92
3 Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	4,447.59	4,924.04	4,447.59	4,924.04
(ii) Trade Payables				
Total Outstanding dues of Micro enterprises and small enterprises ; and	152.40	177.01	152.40	177.01
Total Outstanding dues of Creditors other than Micro enterprises and small enterprises	1,235.32	680.83	1,276.71	714.25
(iii) Other Financial Liabilities	191.96	189.91	191.96	189.91
(b) Other Current Liabilities	52.73	145.22	55.30	143.78
(c) Provisions	111.10	111.10	111.10	111.10
(d) Current tax liabilities(Net)	36.72	0.09	36.72	0.09
TOTAL - EQUITY AND LIABILITIES	16,525.73	16,821.12	15,918.41	16,194.18



Handwritten signature

Cash Flow Statement

Rs. in Lakhs


3	Particulars	Cash Flow Statement			
		Standalone		Consolidated	
		For the Half year ended 30th Sep 2025	For the Half year ended 30th Sep 2024	For the Half year ended 30th Sep 2025	For the Half year ended 30th Sep 2024
		Un-audited	Un-audited	Un-audited	Un-audited
A.	Cash Flow From Operating Activities				
	Profit/(loss) before Tax	150.59	12.39	233.54	(116.00)
	Adjustment for :				
	Finance Costs	283.94	301.43	283.94	301.43
	Depreciation and Amortization Expenses	330.42	299.03	330.42	299.10
	Net (Profit)/Loss on sales/discard of Property ,Plant and Equipment	(0.01)	0.10	(0.01)	0.10
	Provision for Expected Credit Loss	71.80	20.56	71.80	20.56
	Interest Income	(16.51)	(14.52)	(13.30)	(11.50)
	Unspent liabilities written back	(0.26)	-	(0.26)	-
	Unrealised (gain)/loss foreign currency transactions and translation	(56.00)	(28.51)	(131.31)	49.45
	Operating profit before working capital changes	763.97	590.48	774.82	543.14
	Changes in working Capital:				
	(Increase)/Decrease in Inventories	(40.25)	(100.70)	(76.52)	(56.87)
	(Increase)/Decrease in Trade and other Receivables	162.38	87.19	167.51	94.23
	Increase /(Decrease) in Trade and other payable	502.11	621.62	523.53	617.62
	Cash generation from Operation	1,388.21	1,198.59	1,389.34	1,198.12
	(Payment)/refund of Direct Taxes	(2.22)	3.34	(3.25)	3.34
	Net Cash generated from/ (used in) Operating Activities	1,385.99	1,201.93	1,386.09	1,201.46
B.	Cash Flow from Investing Activities				
	Purchase of Property, Plant and Equipment & Intangible Assets including Capital work-in-progress	(235.46)	(579.54)	(235.46)	(579.54)
	Sale of Property, Plant and Equipment	0.05	-	0.05	-
	Investment in Mutual Funds	(10.00)	-	(10.00)	-
	Movement in Term Deposits	32.20	152.41	32.20	152.41
	Interest Received	16.36	5.21	16.36	5.21
	Net Cash generated from/ (used in) Investing Activities	(196.85)	(421.92)	(196.85)	(421.92)
C.	Cash Flow from Financing Activities				
	Receipts from Non Current Borrowings	27.75	444.37	27.75	444.37
	Repayment of Non Current Borrowings	(322.51)	(284.19)	(322.51)	(284.19)
	Loan repaid to/receipt from a Director	3.00	(3.00)	3.00	(3.00)
	Receipts/(Repayment) of Current Borrowings (Net)	(607.13)	(611.79)	(607.13)	(611.79)
	Finance Costs Paid	(282.20)	(311.92)	(282.20)	(311.92)
	Net Cash generated from/ (used in) Financing Activities	(1,181.09)	(766.53)	(1,181.09)	(766.53)
	Net Increase/ (Decrease) in Cash and Cash Equivalents (A+B+C)	8.05	13.48	8.15	13.01
	Add : Opening Cash and Cash Equivalents	2.37	5.36	3.07	7.89
	Closing Cash and Cash Equivalents	10.42	18.84	11.22	20.90

4 These financials results have been prepared in accordance with the Indian Accounting Standards (Ind-AS) prescribed u/s 133 of the companies act, 2013 and other recognised accounting practises and policies to the extent applicable.

5 As the Company's business fall within a single primary business segment viz. sale of capsule, the disclosure requirement of Indian Accounting Standard (Ind AS-108) "Operating Segments" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder, is not applicable.

6 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on November 04, 2025 .

Place: NEW DELHI
Date: 04-11-2025



Anil Khaitan
(Chairman cum Managing Director)
DIN 00759951

Independent Auditor's Review Report on Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2025 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended.

To the Board of Directors of Sunil Healthcare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results ("Statement") of Sunil Healthcare Limited ("the Company") for the quarter and half year ended September 30, 2025. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this Statement based on our review.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement read with notes therein, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place: Noida (Delhi-NCR)
Date: November 4, 2025

For Singhi & Co.
Chartered Accountants
Firm Reg. No. 302049E

Bimal Kumar Sipani
Partner

Membership No. 088926
UDIN: 25088926BMJHQU8089

Independent Auditor's Review Report on unaudited consolidated financial results for the quarter and half year ended September 30, 2025 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended

To Board of Directors of Sunil Healthcare Limited


1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Sunil Healthcare Limited ('the Company/ the Parent') and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and half year ended September 30, 2025, ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of the following foreign subsidiaries:
 - a) Sunil Healthcare Mexico Sa De CV
 - b) Sunil Healthcare North America LLC
5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement read with notes therein, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. The unaudited consolidated financial results include the interim financial results of two foreign subsidiaries which are not required to be audited/reviewed under the law of respective countries of their incorporation, whose interim financial results reflect total assets of Rs. 471.50 lakhs as at September 30, 2025 and total revenue from operation of Rs. Nil and Rs. Nil, net profit after tax of Rs. 20.94 lakhs and Rs. 83.16 lakhs and total comprehensive income of Rs. (12.84) Lakhs and Rs. 7.65 lakhs for the quarter and half year ended September 30, 2025 respectively, and net cash inflow of Rs. 0.10 lakhs for the half year ended September 30, 2025 as considered in the statement. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.



For Singhi and Co.
Chartered Accountants
Firm Reg. No. 302049E

Bimal Kumar Sipani
Partner

Membership No. 088926

UDIN: 25088926BMJHQT1493

Place: Noida (Delhi-NCR)
Date: November 04, 2025